Physician profile
Georges Khoueiry
NPI 1689829087
$16,439.25
in general payments reported to CMS, 2019-2025
45 companies · $4,249 in 2025
The $4,249 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,628 · 2020: $653 · 2021: $949 · 2022: $2,498 · 2023: $1,360 · 2024: $4,102 · 2025: $4,249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,496 · Travel and Lodging: $2,215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,495.89 |
| Travel and Lodging | $2,215.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $7,184.03 | 2021-2025 | Corevalve Evolut R, Hawkone, Abre |
| Abiomed | $2,066.77 | 2019-2025 | Impella |
| Boston Scientific Corporation | $1,776.33 | 2019-2025 | Watchman Flx, Ranger, Emerge Push |
| Shockwave Medical, INC | $959.56 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abbott Laboratories | $775.44 | 2019-2025 | Jot Dx, Aveir, Cardiomems |
| Edwards Lifesciences Corporation | $578.71 | 2022-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Biotronik INC. | $257.09 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $240.19 | 2019-2025 | Lifevest |
| Cardiovascular Systems INC. | $223.40 | 2020-2021 | |
| Philips North America LLC | $207.15 | 2024-2025 | Elca, Igt Devices Systems Undivided, (Ck4) Mcot |
| Angiodynamics, INC. | $184.86 | 2023-2024 | Auryon Laser System 100-120 Vac |
| Pfizer INC. | $152.33 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $151.42 | 2021-2025 | |
| Penumbra, INC. | $147.36 | 2025 | Indigo System |
| E.R. Squibb & Sons, L.L.C. | $143.08 | 2021-2025 | Camzyos |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Georges Khoueiry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.